Neoplasms

Digestive System Diseases

All Conditions

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Antineoplastic Agents

All Drugs and Chemicals

Capecitabine

Apatinib

Oxaliplatin

Protein Kinase Inhibitors

Enzyme Inhibitors

Apatinib combined with CAPEOX program. Apatinib tablets: 500 mg po qd from the second cycle of chemotherapy. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.

CAPEOX program. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.

Apatinib combine with CAPEOX adjuvant chemotherapy for resectable colorectal

CAPEOX adjuvant chemotherapy for resectable colorectal

CAPEOX

Yunhong Tian

Objective: To compare the outcome of patients with colorectal cancer who treated with adjuvant therapy or Apatinib with adjuvant therapy postoperatively.

Language: English.

Apatinib for Resectable Colorectal Cancer

Apatinib With Postoperative Adjuvant Chemotherapy for Operable Colorectal Cancer

Number of Participants recurrence-free survival in intervention group and control group.

Number of Participants overall survival in intervention group and control group.

Nanchong Central Hospital

Principal Investigator

Symptoms and General Pathology

Postoperative Complications

Pyridostigmine Bromide

Patients who used sugammadex Sugammadex 1 vial (200mg) intravenous, at the end surgery, before extubation

Patients who didn't use sugammadex Pyridostigmine 15\~20mg intravenous, at the end of surgery, before extubation

Sugammadex injection as a reverse agent of neuromuscular blocking

Sugammadex

In Kyong Yi, MD

This study is retrospective study. The purpose of this study is checking the effect of sugammadex on the outcome after colorectal surgery. The outcome is compared among the 2 groups, sugammadex group and non-sugammadex group. The primary parameters of outcome are length of stay, readmission rate, postoperative complications, time interval for first successful oral intake.

Abdominal surgery, like colorectal surgery, needs more than moderate neuromuscular block during surgery. After the surgery, reversal agent of neuromuscular blocking agent is given almost every pateints who underwent general anesthesia.

Classic reversal agent is cholinesterase inhibitor, like pyridostigmine and neostigmine. Its action mechanism is competetive antagonist of rocuronium. But cholinesterase inhibitor cannot make complete reversal in moderate or deep neuromuscular block. Its incomplete reversal which is called residual block cause respiratory complications and prolongation hospital stay.

Sugammadex has different mechanism compared to cholinesterase inhibitor. It captures neuromuscular agent, especially rocuronium, and prevent rocuronium's action. Even in deep neuromuscular block, sugammadex can reverse the action of rocuronium, and its reversal effect is fater and more reliable compared to cholinesterase inhibitor.

Previous studies focused on only short term outcome of sugammadex, like postanesthetic care unit (PACU) discharge time, respiratory complications in PACU.

But in this study, longer term outcome will be comapred between sugammadex group and cholinesterase inhibitor group (pyridostigmine).

The Effect of Sugammadex on the Outcome After Colorectal Cancer Surgery

Readmission or ER visit within 30 days after discharge

postoperative complications, heart, lung, kidney, neurovascular, infection etc Check by review discharge summary note, consultation note, and postoperative laboratory tests

time interval between end of surgery and the first successful oral intake

Ajou University School of Medicine

Clinical assistant professor

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Behaviors and Mental Disorders

Rare Diseases

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Anxiety Disorders

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Ovarian Cancer

Ovarian Epithelial Cancer

RFNP was created by researchers. RFNP comprises positive language, a positive environment, relaxation exercise and methods of coping with stress (Mete et al., 2017; Mete et al., 2015; Lazarus, 1984). This programme has a content which reducing women's anxiety and pain. Such programmes are expected to enhanced level of the knowledge about ovarian cancer and its surgery. Women are usually admitted to the clinic two days before surgery. The program duration was for 2 days each day with two sessions, of 6 hr each. There are four relaxation exercises in the program because repetition is recommended for the relaxation exercises to be effective. Deep breathing exercise, progressive muscle relaxation, and guided imagery were used in program. In addition, RFNP is divided into four sections so that the information is not intensely transferred to women.

In the control group, women received routine nursing care in the hospital, and data collection tools were applied at the parallel hours as the experimental group. Usual nursing care included information about visitor and meal times, nurse call button, diet, drug administration and not to leave the hospital. Relaxation exercises were not practiced to patients in usual nursing care to reduce stress and anxiety.

The first two hours after the hospitalization of the patient will be met and the aim of the study will be explained. On the same day, the patient will be given breathing and relaxation exercises and explained why it is important. On the second day after the hospitalization, the patient will be evaluated and the previous day's exercises will be repeated and leg exercises will be performed. The importance of mobilization will then be highlighted. the same day gradual relaxation exercise and surgical relaxation will be administered to the patient three times. The patient will be evaluated on the first postoperative day.

Preoperative Education

Buse Güler, MSc

A randomised controlled trial study consisting of two-group pretest-post-test.

This study was designed as a randomized controlled trial with pretest and posttest model. The sample of the research consisted of patients who would undergo ovarian cancer surgery at the gynecologic oncology unit of a university hospital in Turkey between June 2019-August 2020.

The women were randomly assigned using "a random number generation program (Research Randomizer (https://www.randomizer.org/)" by an independent researcher who was not included in the study, intervention and control groups were formed. Women were not informed about the group they would be a part of. However, the groups of women were known by the researchers.

Preoperative Care In Ovarian Cancer Patients

Preoperative Care in Ovarian Cancer: Effects of Relaxation-Focused Nursing Program in Women With Ovarian Cancer

It has been measured The State and Trait Anxiety Inventory. Form Y, its most popular version, has 20 items for assessing trait anxiety and 20 for state anxiety. State anxiety items include: "I am tense; I am worried" and "I feel calm; I feel secure." Trait anxiety items include: "I worry too much over something that really doesn't matter" and "I am content; I am a steady person." All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always"). Scores range from 20 to 80, with higher scores correlating with greater anxiety.

It has been measured visual analog scale for pain. Scores range from 0 to 10, with higher scores correlating with greater pain.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Apatinib for Resectable Colorectal Cancer	NCT03228043	Apatinib Outcome, Fatal Colorectal Canc... Surgery Adjuvant Chemot...	Apatinib CAPEOX	18 Years - 75 Years	Nanchong Central Hospital
Apatinib for Resectable Colorectal Cancer	NCT03228043	Apatinib Outcome, Fatal Colorectal Canc... Surgery Adjuvant Chemot...	Apatinib CAPEOX	18 Years - 75 Years	Nanchong Central Hospital
The Effect of Sugammadex on the Outcome After Colorectal Cancer Surgery	NCT03619759	Outcome, Fatal	Sugammadex	21 Years - 80 Years	Ajou University School of Medicine
Apatinib for Resectable Colorectal Cancer	NCT03228043	Apatinib Outcome, Fatal Colorectal Canc... Surgery Adjuvant Chemot...	Apatinib CAPEOX	18 Years - 75 Years	Nanchong Central Hospital
Preoperative Care In Ovarian Cancer Patients	NCT04260334	Adnexal Mass Perioperative C... Outcome, Fatal	Preoperative Ed...	18 Years -	Dokuz Eylul University

Spots Global Cancer Trial Database for outcome, fatal